Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4575262 | 0.98 | IDO1 (0.33) | IDO1 | |
| SCHEMBL13006988 | 0.80 | IDO1 (0.35) | IDO1HPGDS | |
| SCHEMBL2702083 | 0.80 | IDO1 (0.36) | IDO1HPGDS | |
| SCHEMBL7468382 | 0.78 | IDO1 (0.35) | IDO1HPGDS | |
| Hydrochloric Acid SCHEMBL28261308 | 0.78 | IDO1 (0.35) | IDO1HPGDS | |
| SCHEMBL2990640 | 0.75 | JAK1 (0.33) | IDO1 | |
| SCHEMBL20364511 | 0.75 | IDO1 (0.30) | IDO1 | |
| SCHEMBL9032459 | 0.75 | TOP2A (0.31) | — | |
| SCHEMBL2990635 | 0.74 | JAK1 (0.35) | — | |
| SCHEMBL26964189 | 0.74 | HTR7 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-108863919-B | Sulfonamide compound for treating gout or hyperuricemia and preparation method thereof | 海创药业股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-108863919-A | For treating the sulfamide compound and preparation method thereof of gout or hyperuricemia | 成都海创药业有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| WO-2003093245-A1 | SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-6403584-B1 | CONJUNCTIVITIS, ALLERGIC RHINITIS, ALZHEIMER'S DISEASE, ASTHMA, ATHEROSCLEROSIS, AUTOLOGOUS BONE MARROW TRANSPLANTATION, ANTIINFLAMMATORY, ETC | MERCK & CO., INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1150997-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000043415-A1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1000051-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0910564-A1 | D-AMINO ACID DERIVED INHIBITORS OF CYSTEINE AND SERINE PROTEASES | CEPHALON, INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0910564-A4 | — | — | 1999-04-28 | — | — | EP | disclosed |
| WO-1999006390-A1 | CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5852007-A | Cysteine and serine protease inhibitors containing D-amino acid at the P2 position, methods of making same, and methods of using same | CEPHALON, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1997021690-A1 | D-AMINO ACID DERIVED INHIBITORS OF CYSTEINE AND SERINE PROTEASES | CEPHALON, INC. (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | IDO1 1166/4885HPGDS 1978/4885ALDH1A1 268/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | IDO1 652/4885HPGDS 1242/4885ALDH1A1 217/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | IDO1 1872/4885HPGDS 348/4885ALDH1A1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.